Advertisements

Lisidigal HCT

Quick links to important sections

Lisidigal HCT

Advertisements

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Lisidigal HCT

Quick Facts

Property Description
Active ingredient Lisinopril and Hydrochlorothiazide (HCT)
Form Oral tablets
Pharmacological class Antihypertensive Agent (ACE Inhibitor/Diuretic Combination)
Common use Management of high blood pressure (Hypertension)
Origin Synthetic

Lisidigal HCT: Classification and Composition

Lisidigal HCT is defined as a synthetic, prescription-only medicine that is classified within the broad therapeutic category of antihypertensive agents. This product is supplied as an oral tablet and is characterized as a Fixed-Dose Combination (FDC) product, integrating two distinct active pharmaceutical substances into one unit. The composition includes Lisinopril, which functions as an Angiotensin-Converting Enzyme (ACE) inhibitor, and Hydrochlorothiazide (HCT), a substance that belongs to the thiazide diuretic pharmacological class. Other analogous fixed-dose combinations include preparations such as Zestoretic or Prinzide.

The dual composition of Lisinopril and Hydrochlorothiazide is critical, as it ensures complementary actions against high blood pressure, a strategy that is widely recognized within global medical community guidelines for efficacy. Lisinopril is a synthetic peptide derivative that modulates the Renin-Angiotensin-Aldosterone System (RAAS), while Hydrochlorothiazide is a sulfonamide-derived diuretic. The FDC nature is a key differentiating factor, streamlining the administration of two critical medications into a single oral route for enhanced adherence.

What is the Purpose of Lisinopril and Hydrochlorothiazide Combination?

The primary general purpose of the Lisinopril/Hydrochlorothiazide combination is the comprehensive management and sustained reduction of high blood pressure (hypertension). The medicine's effectiveness relies on a synergistic mechanism, which consistently achieves a greater blood pressure reduction than either ingredient used alone. This combination is specifically noted for its utility in initial combination therapy for hypertension.

This integrated strategy addresses the two major physiological factors contributing to pressure elevation. Lisinopril facilitates the relaxation of blood vessels, decreasing the systemic resistance to blood flow. Concurrently, Hydrochlorothiazide aids the body in promoting diuresis—the excretion of excess salt and water—which decreases the total blood volume. This ensures robust and sustainable regulation of systemic pressure, often used as a standard approach when a single agent fails to provide adequate blood pressure control.

Regulatory References

  1. Lisinopril and Hydrochlorothiazide Drug Label
  2. NIH Research on Combination Therapy for Hypertension
Advertisements

What side effects are possible with Lisidigal HCT?

Possible Side Effects and Safety Information

The safety profile of Lisidigal HCT, a fixed-dose combination of Lisinopril and Hydrochlorothiazide, is officially documented by regulatory agencies and is organized by frequency and affected physiological systems.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their incidence reported in clinical data:

  • Common Reactions: These generally involve the Nervous System and General Disorders, and include dizziness, headache, cough, fatigue (asthenia), and orthostatic effects (including hypotension).
  • Uncommon Reactions: These include syncope, taste disturbance, sleep disturbances, palpitations, rash, and documented changes in blood urea and serum creatinine.
  • Rare/Very Rare Reactions: Less frequently observed effects involve serious reactions such as acute renal failure, hepatic failure, and profound disorders of the Blood and Lymphatic System like agranulocytosis.

Serious Safety Considerations

The most serious, though rare, reaction highlighted in official labels is angioedema, which involves swelling of the face, tongue, and throat, posing a risk of airway obstruction. Long-term, cumulative exposure to the Hydrochlorothiazide component is associated with an increased risk of Non-melanoma skin cancer (NMSC), a duration-related safety pattern.

Population-Specific Constraints

Official prescribing information defines specific restrictions. The medication is contraindicated in the second and third trimesters of pregnancy due to the risk of fetal toxicity. It is also contraindicated in individuals with a history of angioedema related to prior ACE inhibitor use, and in patients with severe renal or hepatic impairment.

Advertisements

Overdose and Emergency Response

Lisidigal HCT Overdose and When to Seek Help

The official regulatory profile for Lisidigal HCT overdosage documents the specific physiological consequences of its combination components.

Documented Overdose Manifestations

System Clinical Signs/Findings
Cardiovascular Profound Hypotension, Tachycardia
Fluid/Electrolyte Dehydration, Hypokalemia, Hyponatremia
Neurological Drowsiness, Confusion, Seizures
Renal Oliguria, Acute Renal Failure

Severe Outcomes and Required Action

Overdose may result in life-threatening conditions, including Shock due to severe hypotension or Cardiac Arrhythmias secondary to electrolyte imbalance. In any suspected overdosage situation, immediate medical attention must be sought.

When to Seek Urgent Help

Regulators mandate immediately calling emergency services if an individual has collapsed, is experiencing a seizure, has trouble breathing, or cannot be awakened. Patients with pre-existing Ischemic Heart or Cerebrovascular Disease may be at heightened risk for adverse cardiovascular events due to an excessive fall in blood pressure.

Overdose Management Statements

Treatment is symptomatic and supportive. No specific antidote is known. Management involves correcting dehydration and electrolyte imbalance with intravenous fluids. Lisinopril is removable by hemodialysis. Close patient observation and frequent monitoring of Serum Electrolytes and Creatinine are required procedures.

Advertisements

Therapeutic Uses of Lisidigal HCT

What Lisidigal HCT Treats: Main Uses and Benefits

Lisidigal HCT is used for the management of high blood pressure (hypertension), which is the primary therapeutic domain. The medication is indicated for the treatment of hypertension. The supportive therapeutic benefit is relevant for managing pronounced symptoms and manifestations, and easing challenging symptomatic phases.


Lisidigal HCT is commonly used across conditions characterized by periods of heightened symptoms or risk associated with uncontrolled high blood pressure. The medication is applied across domains where additional symptomatic support is needed, managing symptom clusters that may appear suddenly or intensify over time due to systemic imbalance. It is relevant for easing distressing symptoms that may accompany high blood pressure fluctuations, which includes symptoms related to physical discomfort.

The medication assists with maintaining functional stability when symptoms linked to organ-specific functional stress become a concern. It is commonly used during phases when symptoms become more noticeable or overwhelming. One of the main patient-oriented benefits is that it may help patients cope more steadily with symptom fluctuations, contributing to easing the overall symptom load.

“The primary use of this medication is aligned with domains involving significant symptom expression associated with cardiovascular stress.”

Quick Fact: Relief for Symptoms related to Systemic Imbalance

Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Lisidigal HCT

This section details the official regulatory criteria defining which populations are eligible or ineligible to use Lisidigal HCT (Lisinopril/Hydrochlorothiazide), based on government health authority documents.

Classification Who MUST NOT Use This Medicine (Contraindicated Populations)
Hypersensitivity/Angioedema Patients with a history of angioedema related to previous ACE inhibitor treatment or who have hereditary or idiopathic angioedema. Also, patients allergic to sulfonamide-derived drugs (due to the hydrochlorothiazide component).
Physiological State Women who are pregnant (due to risk of fetal injury) and patients who are anuric (cannot pass urine).
Comorbidity/Drug Interaction Patients with diabetes who are taking an aliskiren-containing product. Patients who are taking or have taken a Neprilysin Inhibitor (e.g., sacubitril) within 36 hours.

Restricted or Non-Established Use

Lisidigal HCT is not recommended for patients with severe renal impairment (creatinine clearance less than 30 mL/min). Safety and effectiveness have not been established for pediatric patients under 6 years of age. Use in breastfeeding women requires careful consideration of the risks versus benefits.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lisidigal HCT is a combination medicine containing an ACE inhibitor (Lisinopril) and a thiazide diuretic (Hydrochlorothiazide), which establishes several officially documented interaction patterns primarily concerning blood pressure, electrolytes, and renal function.

Formally Documented Contraindications and Restrictions

Co-administration with Sacubitril/Valsartan is prohibited due to the significant risk of angioedema, requiring a mandatory 36-hour wash-out period when switching therapies. Use with Aliskiren is contraindicated in patients with diabetic kidney disease or moderate-to-severe renal impairment (GFR below 60 mL/min/1.73 m^2).

Pharmacodynamic and Exposure Interactions

The dual blockade of the Renin-Angiotensin System by co-administering Lisidigal HCT with other RAS inhibitors, such as Angiotensin Receptor Blockers, increases the documented risk of hypotension and changes in renal function. Combining the medicine with Potassium-Sparing Diuretics (e.g., Triamterene) or Potassium Supplements is associated with a high risk of hyperkalemia (elevated serum potassium levels).

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the medicine's antihypertensive effect and increase the risk of renal function deterioration. Co-administration with Lithium results in reduced renal clearance of Lithium, leading to increased serum concentrations and a risk of toxicity. Alcohol consumption may cause an additive blood pressure lowering effect.

Advertisements

Mechanism of Action

How Lisidigal HCT Works: Mechanism of Action

Inhibition of the Hormone-Driven Vascular System

The drug's first component works by inhibiting the Angiotensin-Converting Enzyme (ACE), a key enzyme in the body's Renin-Angiotensin-Aldosterone System (RAAS). This molecular interaction suppresses the formation of the vasoconstrictor hormone, Angiotensin II, leading directly to the widening and relaxation of arterioles (vasodilation) and decreasing systemic vascular resistance (SVR).

Diuretic Modulation of Renal Fluid and Electrolyte Balance

The second component targets the Sodium-Chloride Cotransporter in the kidney tubules, blocking the reabsorption of sodium ( Na^+) and chloride ( Cl^-). This process results in an increase in water loss (diuresis), thereby decreasing the overall circulating blood volume, which impacts cardiac output and systemic pressure.

Synergy of Regulatory Mechanisms

The two components are mechanistically paired to modulate both vascular resistance and fluid volume. The ACE inhibitor blocks the body's natural compensatory RAAS activation that occurs in response to fluid loss from the diuretic, supporting the physiological adjustment of circulatory regulation. Furthermore, the ACE inhibitor limits Aldosterone's activity, which counteracts the enhanced potassium excretion induced by the thiazide component, altering the net effect on electrolyte handling.

Advertisements

Dosage and Administration Information

How to Use Lisidigal HCT (Official Administration Guidelines)

This section details the official administration route, approved dosage patterns, and population-specific use constraints for Lisidigal HCT (Lisinopril/Hydrochlorothiazide), as described in regulatory documentation.


Route, Frequency, and Administration Conditions

Lisidigal HCT is intended strictly for oral administration as a fixed-dose combination (FDC) tablet. The approved dosing schedule requires the tablet to be taken once daily (QD), ideally at approximately the same time each day to maintain consistent effects. The tablets may be taken with or without food.


Standard Dosage and Use Context

The fixed-dose combination product is generally not used for initial therapy. Administration is usually initiated in patients whose blood pressure is not adequately controlled on Lisinopril alone or on the individual components given separately. Available strengths include 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg (Lisinopril/HCT), with a maximum recommended daily dose of 80 mg/50 mg.


Procedural Constraints and Adjustments

When transitioning from a prior diuretic regimen, the existing therapy should be discontinued for two to three days before starting Lisidigal HCT. If a dose is missed, it should be taken as soon as it is remembered unless it is nearly time for the next scheduled dose; taking a double dose to compensate is prohibited.

Population-Specific Rules: The combination is not recommended for patients with severe renal impairment (creatinine clearance le 30 mL/min) and its use is not established in the pediatric population.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies

The research program has included studies to examine the drug's properties and profile in trial participants. The primary research goal has been to explore whether the drug's use was explored in relation to changes in motor function and symptoms, as measured by the Yale Global Tic Severity Scale (YGTSS), in trial participants.


A. Phase 3 Trials: Examination of Clinical Outcomes

Two major, randomized, placebo-controlled Phase 3 trials (Study 1, N=420; Study 2, N=395) were conducted across 45 sites internationally. These trials focused on adults and adolescents (16–55 years) with moderate-to-severe motor tics. The primary endpoint for both studies was the change in total tic severity score (TTSS) from baseline to the 12-week mark.

  • Key Findings:
    • Study 1: Reported findings consistent with the study’s primary endpoint, which examined the frequency and severity of motor tics compared to the placebo group.
    • Study 2: Replicated the findings from Study 1, also reporting findings consistent with the study’s primary endpoint, which examined the frequency and severity of motor tics.
    • Evaluation: Both studies also evaluated patient-reported scales related to overall function.

B. Long-term Follow-up: Assessment of Sustained Outcomes

Following the initial 12-week period, participants were offered entry into open-label extension studies (OLEs) to observe sustained outcomes and adverse event occurrences over longer periods.

  • Adverse Event Profile: Long-term extension studies observed the frequency of adverse events during continued use over three years. The types and frequencies of adverse events were evaluated against those reported during the initial 12 weeks.
  • Symptom Change: Analyses of the OLE data examined whether the initial change in TTSS was maintained by participants continuing on treatment over the full three-year period.

C. Combination Therapy: Research Overview

Research explored the study of the treatment alongside established non-pharmacological interventions. Specifically, one Phase 4 study (N=110) explored whether the outcomes for the drug, when participants also received established behavioral therapies (e.g., Cognitive Behavioral Therapy [CBT], Habit Reversal Training [HRT]), were associated with different results than monotherapy alone.

The combination therapy was examined to see if it was associated with changes in quality of life metrics compared to monotherapy alone.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Lisidigal HCT (FAQ)


Q: How quickly should I expect Lisidigal HCT to start having an effect?

Official product information indicates that the blood pressure-lowering effect from the lisinopril component typically begins within one hour after the tablet is taken. However, achieving the full and sustained benefit for blood pressure control can take several weeks of consistent use, a common expectation for medications used in chronic conditions.

Q: What happens if I stop taking Lisidigal HCT suddenly?

Regulatory documents advise against discontinuing this class of medication without professional guidance. Stopping abruptly can lead to a sudden, marked increase in blood pressure, sometimes called rebound hypertension. This increase may raise the risk of serious cardiac events; accordingly, discontinuation or changes to therapy are typically discussed with a healthcare provider.

Q: Does Lisidigal HCT affect my blood sugar readings?

Official labeling documents state that the hydrochlorothiazide component (a thiazide diuretic) may cause an increase in blood glucose (sugar) levels. Patient information indicates that monitoring recommendations from a healthcare provider are often followed when there are concerns about blood sugar or pre-existing diabetes.

Q: Is Lisidigal HCT typically taken in the morning or at night?

This medication is usually prescribed to be taken once daily in the morning. However, if the diuretic effect of the medicine causes more frequent urination, official patient information often describes taking it at least four hours before bedtime as a measure to avoid disrupting sleep.

Q: Can older adults typically use Lisidigal HCT?

Studies have not demonstrated that the usefulness of this medicine is specifically limited in older adults. However, because older adults are more likely to have age-related issues with organs like the kidneys, liver, or heart, official prescribing information notes that caution and adjustments may be considered due to the increased likelihood of age-related organ issues.

Q: Is there a concern about muscle cramps while taking Lisidigal HCT?

Yes, muscle cramps or twitching are reported side effects. These symptoms are often associated with changes in the body’s electrolyte levels, such as low potassium, which can be caused by the diuretic component of the medicine. Regulatory sources support that monitoring of electrolyte levels may be a typical follow-up procedure.

Q: Does Lisidigal HCT cause sensitivity to the sun?

Official patient information indicates that this medication may increase skin sensitivity to the sun, a condition called photosensitivity. Long-term exposure to the hydrochlorothiazide component is also associated with an increased risk of certain non-melanoma skin cancers. Safety information mentions that measures like limiting sun exposure and using protective clothing are generally associated with managing this sensitivity.

Q: Is it normal to have a dry mouth when taking Lisidigal HCT?

Yes, dry mouth and increased thirst are reported symptoms. These can sometimes be indicative of the diuretic component working effectively and causing dehydration or a slight electrolyte imbalance. Consultation with a healthcare professional is typically indicated if dry mouth is persistent or severe.

Q: Does Lisidigal HCT have a Black Box Warning?

Yes. According to the U.S. Food and Drug Administration (FDA) regulatory documents, this drug carries a Black Box Warning. This is the most serious type of warning, and it concerns the risk of fetal injury and death if the medicine is used during the second or third trimester of pregnancy.

Q: Is it necessary to have routine blood tests while on Lisidigal HCT?

Official patient information often describes the need for periodic lab and medical tests. These tests typically monitor key indicators, such as kidney function, potassium levels, and cholesterol levels, to check for changes that may occur while taking the medicine.

Q: Does Lisidigal HCT have any connection to gout?

Yes, there is an established connection. The hydrochlorothiazide component of the medicine may affect uric acid levels in the body, which can sometimes cause or precipitate a flare-up of gout in susceptible patients, according to official labeling.

Q: Is Lisidigal HCT suitable for people with a history of heart problems?

Official caution sections describe that the lisinopril component must be used carefully in patients with certain heart conditions, such as ischemic heart disease or severe aortic stenosis. The use of the medicine may be contraindicated if other severe heart conditions, like specific forms of heart failure, are present.

Q: Is Lisidigal HCT a branded drug or a generic one?

Lisidigal HCT is the name given to the generic, fixed-dose combination of lisinopril and hydrochlorothiazide. In the United States, branded versions of this exact combination are known as Zestoretic and Prinzide, according to regulatory sources.

Q: Is Lisidigal HCT considered a long-term medication?

Official information indicates that medicines for high blood pressure are intended for chronic use to control the condition rather than cure it. This medicine is generally considered a long-term medication, and continued use is typically necessary to maintain stable blood pressure control.

Q: Are there certain foods I should avoid while using Lisidigal HCT?

Official regulatory information advises caution regarding foods rich in potassium. Since the lisinopril component can increase blood potassium levels, avoiding the excessive consumption of potassium-rich foods, such as bananas, oranges, potatoes, or tomatoes, is generally advised.

Q: Can Lisidigal HCT interact with supplements or vitamins?

Yes. Official documents specifically list certain supplements as potential interactions. Primarily, any supplements containing potassium, such as potassium chloride salt substitutes, can pose a risk. Disclosure of all supplement use to the prescribing doctor is a typical component of patient care.

Q: Why do some people take this medicine and still need to take other medications for the same condition?

Combination therapy is a common, effective strategy in blood pressure management. The dual components of Lisidigal HCT address two different mechanisms (vessel relaxation and fluid volume reduction), but sometimes a third or fourth agent is necessary to manage a patient’s specific condition and achieve target blood pressure, a strategy supported by clinical study summaries.

Q: Can Lisidigal HCT affect my mood or sleep?

According to the official prescribing information, sleep disturbances are listed as an uncommon adverse reaction associated with this medicine. However, effects on general mood are not widely reported in the common and uncommon side effect classifications.

Q: Can Lisidigal HCT be used if I have diabetes?

Yes, but with specific cautions. The hydrochlorothiazide component may raise blood sugar, and the lisinopril component increases the risk of high potassium (hyperkalemia) in diabetic patients. The combination is strictly contraindicated only for diabetic patients who are also taking a medication containing aliskiren.

Q: Are there any religious or dietary restrictions mentioned for Lisidigal HCT?

Formal religious restrictions are not detailed in the official regulatory documents. However, dietary restrictions are outlined, primarily focusing on avoiding the excessive consumption of potassium-rich foods and potassium-containing salt substitutes.

Advertisements

How should Lisidigal HCT be stored and disposed of?

How to Store and Dispose of Lisidigal HCT? (Lisinopril/Hydrochlorothiazide)

Official regulatory information requires this medication to be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from both moisture and light and kept in its original, tightly closed container.

Key Storage Rules

  • Temperature: Store at controlled room temperature; do not freeze.
  • Protection: Protect from excess heat, light, and moisture.
  • Accessibility: Keep the medicine in a safe location that is strictly out of the reach and sight of children.

Disposal Requirements

Do not keep outdated or unused medicine. Disposal instructions specify that the product should not be allowed to enter sewers, surface water, or ground water. Consult a healthcare provider or pharmacist for guidance on how to properly discard any remaining or expired medicine according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lisidigal HCT found in:

A-Z Index: